Drug discovery needs of R&D Committee member companies
This web page summarizes the drug discovery needs of R&D committee member companies for academia and startups.
- Click on to the company name to access each company's innovation-related website.
- Some companies have messages and contact information for academia and startups listed under their name.
- Please check the information for each company and contact them directly according to your wishes.
A
ASAHI KASEI PHARMA CORPORATION
Asahi Kasei Pharma aims to enrich the lives of people around the world through the research and development of new drugs and pharmaceutical technologies.
To achieve the goal, we have been promoting open innovation activities worldwide. These activities include the introduction of cutting-edge technologies, partnership, and research collaboration. We are focusing on facilitating the discovery of preclinical lead compounds and improving the drug development process.
Astellas Pharma Inc.
AstraZeneca K.K.
C
CHUGAI PHARMACEUTICAL CO., LTD.
D
DAIICHI SANKYO CO., LTD.
Daiichi Sankyo is actively engaged in the expansion of its external drug discovery network and the acquisition of diverse sources of innovation as part of its open innovation activities. We are particularly focused on identifying novel drug targets, developing valuable evaluation systems for research, and exploring new modality technologies. For more information, we encourage you to visit our company's official website.
Contact：OpenInnovation@daiichisankyo.co.jp
E
Eisai Co., Ltd.
Eisai aims for the development of therapeutic drugs targeting Alzheimer's disease and broader dementia, following amyloid β and tau, and is seeking proposals from scientists with unique ideas and research programs in these areas. For more detailed information, please see our corporate website.
K
KISSEI PHARMACEUTICAL CO., LTD.
We are focusing on the following key areas: urology, renal diseases and dialysis, rare and intractable diseases. We concentrate our investment of management resources into these areas, and are working actively on the creation of pharmaceuticals with high originality and competitive advantage. In addition, in the field of in-house drug discovery, we focus on small molecule pharmaceuticals discovery and strive to enhance our capabilities in compound creation and evaluation techniques, aiming to create innovative and useful new drugs that can take advantage of the strengths. We leverage open innovation and digital technologies, including AI, to pursue the speed and quality of our drug discovery research.
Kowa Company, Ltd.
Target Areas of R&D
- Lifestyle-related diseases（Dyslipidemia, Type 2 Diabetes, Arteriosclerotic disease）
- Immunity Inflammation（Autoimmune disease, Inflammatory disease, Skin disease）
- Sensory organ diseases（Eye disease, Equilibrium and auditory function disorders）
Kyowa Kirin Co., Ltd.
M
MARUHO CO., LTD.
Please follow the link below.
Licenses and Partnering Enquiries
MITSUBISHI TANABE PHARMA CORPORATION
Mitsubishi Tanabe Pharma is seeking partnerships with companies, universities, and research institutions in the following areas and fields related to drug discovery and R & D．
Target areas/fields: Neurological disorders, autoimmune diseases, cancer, and drug discovery technologies related to the above-mentioned disease areas.
For more details, please contact us.
Contact：partnering-ml@ml.mt-pharma.co.jp
MOCHIDA PHARMACEUTICAL CO., LTD.
Mochida Pharmaceutical’s drug discovery research is focusing on "oligonucleotide drugs" to create innovative new drugs that address unmet medical needs. All of our researchers are working together to maximize the unique properties of oligonucleotide drugs and to create original and unprecedented pharmaceuticals.
Contact：moire.info@mochida.co.jp
N
NIPPON BOEHRINGER INGELHEIM CO., LTD.
Contact：BIAlliance.JP@boehringer-ingelheim.com
NIPPON KAYAKU CO., LTD.
The Pharmaceutical Research Laboratories are vigorously pursuing R&D on new anti-cancer drugs using small molecule drug development, biotechnology, and polymer synthesis technologies, while conducting joint research with multiple external research institutions. If you have a proposal for joint research, please contact us using the "Inquiry Form" below.
Contact：Inquiry form
NIPPON SHINYAKU Co., Ltd.
We are actively seeking collaboration opportunities in seeds, targets, and technologies for drug discovery.
For more information, please visit our R&D partnering website.
Contact：zz_mail_partnering@po.nippon-shinyaku.co.jp
O
ONO PHARMACEUTICAL CO., LTD.
Our drug discovery policy is "developing original and innovative new drugs." We focuses on the areas of oncology, immunology, neurology and specialties; all of which include diseases with high medical needs.
Contact：customer_info@ono-pharma.com
OTSUKA PHARMACEUTICAL Co., Ltd.
Disease area of interest
Neuropsychiatry, Neurodegenerative diseases, Renal and cardiovascular diseases, Autoimmune diseases, Immunology/Inflammatory diseases, Hematological cancer, Ophthalmology, Rare diseases
Contact：OPC_Partnering@otsuka.jp
P
PFIZER JAPAN INC.
S
Sanofi K.K
SHIONOGI & CO., LTD.
SHIONOGI will continue to create new drugs by focusing on research areas related to "Protect people from the threat of infectious diseases" and "Contribute to a healthy and prosperous life". In order to effectively find various partnership opportunities, we have published a Wish List of research activities on our website. If you have any suggestions or inquiries, please register using the inquiry form linked below.
Contact：https://fofa.jp/song/a.p/109/
Sumitomo Pharma CO., LTD.
Toward continuous new drug discoveries, we, Sumitomo Pharma, are actively pursuing research collaborations with research institutions, including universities, in Japan and overseas, investing in venture companies with innovative technologies, and making acquisitions and in-licensing products under development through strategic investments to expand and strengthen our development pipeline.
https://www.sumitomo-pharma.com/rd/research-alliances/
Please access to the following URL and fill out the inquiry form.
https://www.sumitomo-pharma.com/inquiry/rd/
T
TAKEDA PHARMACEUTICAL COMPANY LIMITED
TEIJIN PHARMA Limited
Teijin Pharma Ltd. is promoting the following open innovation activities:
- Drug Targets, Drug Seeds, and Novel Evaluation Systems for Neurodegenerative Diseases and Autoimmune Diseases.
- Novel Modality Technologies Applicable to Rare Diseases and Other Conditions.
- Drug Delivery Technologies to Specific Tissues, such as Crossing the Blood-Brain Barrier.
We welcome your proposals at early research stage, regardless of drug seeds acquisition.
Contact：
Kazuya Takenouchi, Ph.D., Teijin Institute for Bio-Medical Research
k.takenouchi@teijin.co.jp